




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :  A61K 35/14, 39/02, 39/12, 39/385, 39/395, C12N 5/08, G01N 33/554		A1	(11) International Publication Number: WO 97/22349  (43) International Publication Date: 26 June 1997 (26.06.97)
(21) International Application Number: PCT/US96/19954  (22) International Filing Date: 17 December 1996 (17.12.96)  (30) Priority Data: 08/575,432 20 December 1995 (20.12.95) US		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, FI, GE, HU, IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(71) Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY [US/US]; Suite 350, 900 Welch Road, Palo Alto, CA 94304 (US).  (72) Inventors: ENGLEMAN, Edgar, G.; 60 Lane Place, Atherton, CA 94027 (US). LEVY, Ronald; 966 Mears Court, Stanford, CA 94305 (US). HSU, Frank; 761A Loma Verde Avenue, Palo Alto, CA 94306 (US). BENIKE, Claudia; 4388 Lorren Drive, Fremont, CA 94536 (US).  (74) Agents: FRIEBEL, Thomas, E. et al.; Pennie & Edmonds, 1155 Avenue of the Americas, New York, NY 10036 (US).		Published With international search report.	

(54) Title: METHODS FOR IN VIVO T CELL ACTIVATION BY ANTIGEN-PULSED DENDRITIC CELLS



## (57) Abstract

The present invention relates to methods of using isolated human dendritic cells to present exogenous antigens for the induction of immune responses *in vivo*. In particular, it relates to the isolation of dendritic cells from human blood, exposing the cells to lymphoma-derived immunoglobulins or to proteins derived from human immunodeficiency virus (HIV) as antigens, and infusing the antigen-pulsed dendritic cells into patients to induce and/or augment an antigen-specific immune response. The methods of the invention described herein have a wide range of applications, including, but not limited to, the clinical use of antigen-pulsed dendritic cells as vaccines and/or immunotherapeutics against cancer and infectious agents such as viruses.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

**METHODS FOR IN VIVO T CELL ACTIVATION  
BY ANTIGEN-PULSED DENDRITIC CELLS**

**1. INTRODUCTION**

5       The present invention relates to methods of using isolated human dendritic cells to present exogenous antigens for the induction of immune responses *in vivo*. In particular, it relates to the isolation of dendritic cells from human blood, 10 exposing the cells to lymphoma-derived immunoglobulins or proteins derived from human immunodeficiency virus (HIV) as antigens, and infusing the antigen-pulsed dendritic cells into patients to induce and/or augment an antigen-specific immune response. The methods of 15 the invention described herein have a wide range of applications, including but not limited to, the clinical use of antigen-pulsed dendritic cells as vaccines and/or immunotherapeutics against cancer and infectious agents such as viruses.

20

**2. BACKGROUND OF THE INVENTION**

**2.1. GENERATION OF AN IMMUNE RESPONSE**

25       The introduction of a foreign antigen into an individual elicits an immune response consisting of two major components, the cellular and humoral immune responses, mediated by two functionally distinct populations of lymphocytes known as T and B cells, respectively. The T cells may be further divided into 30 two subsets by function and phenotype. A subset of T cells responds to antigen stimulation by producing lymphokines which "help" or activate various other cell types in the immune system. Another T cell subset is capable of developing into antigen-specific 35 cytotoxic effector cells, being able to directly kill antigen-positive target cells. On the other hand, the

B cell response is primarily carried out by secretory proteins, antibodies. Antibodies function by neutralizing antigens or in conjunction with other 5 effector cells of the immune system in mediating antibody-dependent cellular cytotoxicity.

Helper T cells ( $T_H$ ) can be distinguished from classical cytotoxic T lymphocytes (CTL) and B cells by their cell surface expression of a 10 glycoprotein marker termed CD4. Although the mechanism by which CD4 $^+$   $T_H$  function has not been fully elucidated, the existence of functionally distinct subsets within the CD4 $^+$  T cell compartment has been reported (Mosmann and Coffman, 1989, Ann. Rev. 15 Immunol. 7:145-173). In the mouse, type 1 helper T cells ( $T_{H1}$ ) produce interleukin-2 (IL-2) and  $\gamma$ -interferon ( $\gamma$ -IFN) upon activation, while type 2 helper T cells ( $T_{H2}$ ) produce IL-4 and IL-5. Based on the profile of lymphokine production,  $T_{H1}$  appear to be 20 involved in promoting the activation and proliferation of other T cell subsets including CTL, whereas  $T_{H2}$  specifically regulate B cell proliferation and differentiation, antibody synthesis, and antibody class switching. Some CD4 $^+$  T cells, like CD8 $^+$  CTL, 25 appear to be capable of cytotoxic effector function as well.

A second T cell subpopulation is the classical CTL which express the CD8 surface marker. Unlike most  $T_H$ , these cells display cytolytic activity 30 upon direct contact with target cells, although they are also capable of producing certain lymphokines. *In vivo*, CTL function is particularly important in situations where an antibody response alone is inadequate. There is a preponderance of experimental 35 evidence that CTL rather than B cells and their

antibody products play a principal role in the defense against viral infections and cancer.

A salient feature of both T and B cell responses is their exquisite specificity for the immunizing antigen; however, the mechanisms for antigen recognition differ between these two cell types. B cells recognize antigens by antibodies, either acting as cell surface receptors or as secreted proteins, which bind directly to antigens on a solid surface or in solution, whereas T cells only recognize antigens that have been processed or degraded into small fragments and presented on a solid phase such as the surface of antigen-presenting cells (APC). Additionally, antigenic fragments must be presented to T cells in association with major histocompatibility complex (MHC)-encoded class I or class II molecules. The MHC refers to a cluster of genes that encode proteins with diverse immunological functions. In man, the MHC is known as HLA. MHC class I gene products are found on all somatic cells, and they were originally discovered as targets of major transplantation rejection responses. Class II gene products are mostly expressed on cells of various hematopoietic lineages, and they are involved in cell-cell interactions in the immune system. Most importantly, MHC-encoded proteins have been shown to function as receptors for processed antigenic fragments on the surface of APC (Bjorkman et al., 1987, Nature 329: 506-512).

## 2.2. ANTIGEN PRESENTING CELLS

The presentation of antigens to T cells is carried out by specialized cell populations referred to as APC. Typically, APC include macrophages/monocytes, B cells, and bone marrow-

derived dendritic cells (DC). DC are sometimes also referred to as "professional" APC. APC are capable of internalizing exogenous antigens, cleaving them into smaller fragments in enzyme-rich vesicles, and coupling the fragments to MHC-encoded class I or class II products for expression on the cell surface (Goldberg and Rock, 1992, Nature 357:375-379). Since APC express both MHC-encoded class I and class II glycoproteins, they can present antigenic fragments to both CD4<sup>+</sup> and CD8<sup>+</sup> T cells for the initiation of an immune response.

By definition, APC not only can present antigens to T cells with antigen-specific receptors, but can provide all the signals necessary for T cell activation. Such signals are incompletely defined, but probably involve a variety of cell surface molecules as well as cytokines or growth factors. Further, the factors necessary for the activation of naive or unprimed T cells may be different from those required for the re-activation of previously primed memory T cells. The ability of APC to both present antigens and deliver signals for T cell activation is commonly referred to as an accessory cell function. Although monocytes and B cells have been shown to be competent APC, their antigen presenting capacities *in vitro* appear to be limited to the re-activation of previously sensitized T cells. Hence, they are not capable of directly activating functionally naive or unprimed T cell populations.

Although it had been known for a long time that APC could process and present antigens to T cells, it was not shown until relatively recently that small antigenic peptides could directly bind to MHC-encoded molecules (Babbit et al., 1985, Nature 317: 359; Townsend et al., 1986, Cell 44: 959). However,

it is believed that normally, complex antigens are proteolytically processed into fragments inside the APC, and become physically associated with the 5 MHC-encoded proteins intracellularly prior to trafficking to the cell surface as complexes. Two distinct pathways for antigen presentation have been proposed (Braciale et al., 1987, Immunol. Rev. 98: 95-114). It was thought that exogenous antigens were 10 taken up by APC, processed and presented by the exogenous pathway to class II-restricted CD4<sup>+</sup> T cells, while the endogenous pathway processed intracellularly synthesized proteins, such as products of viral genes in virally-infected cells, for association with MHC 15 class I proteins and presentation to CD8<sup>+</sup> CTL. Although the two pathways in antigen processing and presentation may still be correct in some respects, the distinction is blurred in light of recent findings 20 that exogenously added antigens may also be presented to class I-restricted CTL (Moore et al., 1988, Cell 54: 777).

The term "dendritic cell" refers to a diverse population of morphologically similar cell types found in a variety of lymphoid and non-lymphoid 25 tissues (Steinman, 1991, Ann. Rev. Immunol. 9:271-296). These cells include lymphoid DC of the spleen, Langerhans cells of the epidermis, and veiled cells in the blood circulation. Although they are collectively classified as a group based on their 30 morphology, high levels of surface MHC class II expression, and absence of certain other surface markers expressed on T cells, B cells, monocytes, and natural killer cells, it is presently not known whether they derive from a common precursor or can all 35 function as APC in the same manner. Further, since the vast majority of published reports have utilized

DC isolated from the mouse spleen, results from these studies may not necessarily correlate with the function of DC obtained from other tissue types.

- 5    5 (Inaba et al., 1987, J. Exp. Med. 166:182-194; Hengel et al., 1987 J. Immunol., 139:4196-4202; Kast et al., 1988, J. Immunol., 140:3186-3193; Romani et al., 1989, J. Exp. Med. 169:1169-1178; Macatonia et al., 1989, J. Exp. Med. 169:1255-1264; Inaba et al., 1990, J. Exp. Med. 172:631-6640). For example, despite high levels 10 of MHC class II expression, mouse epidermal Langerhans cells, unlike splenic DC, are not active APC in mixed leucocyte reaction (MLR), unless cultured with granulocyte-macrophage colony stimulating factor 15 (GM-CSF) (Witmer-Pock et al., 1987, J. Exp. Med. 166:1484-1498; Heufler et al., 1988, J. Exp. Med. 167:700-705). Most human Langerhans cells express the CD1 and CD4 markers, while freshly isolated blood DC express CD4 weakly, but not CD1. On the other hand, 20 cultured peripheral blood DC express CD1c, but not CD4. Additionally, it has not been established the extent to which the functional characteristics observed with mouse DC are applicable to human DC, especially the DC obtained from non-splenic tissues; 25 in part, due to inherent differences between the human and murine immune systems.

In addition, the biological activity of human DC *in vivo* has not been studied prior to the present invention. Although murine DC exposed to 30 idiotype proteins of mouse lymphoma cells have been reported to induce tumor immunity *in vivo*, such success has not been demonstrated in human patients (Bohlen et al., 1991, International Publication No. WO91/13632). There is no indication in the art that 35 such an approach is suitable for clinical use. In fact, it is well known in the art that cancer is a

complicated disease, and therapy performed in animal models does not adequately predict its likelihood of success in humans. Similarly, acquired  
5 immunodeficiency syndrome (AIDS) caused by HIV does not have a correlative rodent animal model that is useful for assessing anti-HIV therapeutics. Both the efficacy and toxicity of a therapeutic regimen for human disorders can only be properly examined in a  
10 clinical setting where all variable factors are present.

### 3. SUMMARY OF THE INVENTION

The present invention relates to the use of  
15 isolated and antigen-pulsed human DC as APC *in vivo* to induce and/or augment antigen-specific immune responses. It also relates to pharmaceutical composition containing such cells.

The invention is based, in part, on the  
20 Applicants' discovery that human DC partially purified from human blood by sequential density gradient centrifugation function as potent APC *in vivo* in patients with B cell lymphomas. As shown in Example 6, *infra*, when isolated autologous DC are pulsed with  
25 immunoglobulin "custom made" from four patients' lymphoma cells and re-infused into the patients, idiotype-specific T cell proliferative responses are detected. Most importantly, one patient's tumor undergoes a complete regression over the course of  
30 such treatment. This patient also developed a tumor-specific CTL response. In addition, Example 7, *infra*, further demonstrates that HLA-matched donor DC pulsed with a recombinant HIV envelope protein, gp160, induce HIV-specific T cell proliferative and cytotoxic  
35 responses, upon their infusion into an HIV-seropositive recipient.

A wide variety of uses is encompassed by the invention described herein, including but not limited to, the *in vivo* administration of antigen-pulsed DC as vaccines for priming primary immune responses and/or as immunotherapeutics for augmenting secondary immune responses. Such responses may be induced against any antigen of interest, ranging from tumor antigens such as lymphoma idiotypes, p53 tumor suppressor protein, 10 human prostate carcinoma antigen known as prostatic acid phosphatase, melanoma antigens MAGE and MART-1, and oncogene products to infectious agents, including viruses such as HIV and its encoded antigenic products.

15

**4. BRIEF DESCRIPTION OF THE DRAWINGS**

FIG. 1 Peripheral blood lymphocytes were isolated by "FICOLL/HYPAQUE" gradient centrifugation of patient's blood drawn at the indicated 20 point in her therapy regimen. Cells were plated at  $4 \times 10^5$  cells/microtiter well with KLH or autologous immunoglobulin idiotype in Iscove's modified Dulbecco's medium (IMDM) with 1% human AB serum. After 3 days of culture, the cells were split and fed with 25 IMDM containing 5% FCS and 30 units/ml of IL-2. After a total of 5 days at 37°C in 5% CO<sub>2</sub> atmosphere, the cells were pulsed for 16 hours with 1  $\mu$ ci/well <sup>3</sup>H-thymidine. Data are expressed as mean counts/minute of 30 quadruplicate cultures.

FIG.  
2A-2D Contiguous computerized tomographic scans of 35 the chest were obtained prior to treatment with immunoglobulin-pulsed DC and two months following the fourth immunization (optional booster). FIG. 2A and B demonstrate the

regression of paraaortic adenopathy. FIG. 2C and D demonstrate the regression of a paracardiac mass and paraaortic adenopathy. Prior to treatment, these nodal masses were documented to be slowly progressing.

FIG. 3 Peripheral blood mononuclear cells ( $10^5$  per well) from an HIV-infected individual with a CD4 count of 480 CD4 cells per  $\mu\text{l}$ . were cultured with purified HIV-1 MN gp160 (Immuno AG, Vienna, Austria) for 7 days. [ $^3\text{H}$ ]-thymidine was added during the last 12 hours of culture and [ $^3\text{H}$ ]-thymidine incorporation determined using standard methods. The patient was infused monthly with DC pulsed with gp160 (arrows). Peripheral blood mononuclear cells were collected one week after each infusion, and at one and two weeks before the first infusion. Results are expressed as stimulation index (S.I.); counts per minute with antigen/counts per minute without antigen.

FIG. 4 Autologous Epstein Barr virus-transformed B cells were pulsed with vaccinia constructs that carried the HIV env gene or the  $\beta$  galactosidase gene and used as target cells. Peripheral blood mononuclear cells were isolated from the HIV-infected individual and then incubated with the target cells infected with vaccinia virus. Standard chromium release assays were performed one week after each infusion, and at one and two weeks before the first infusion. Patient

- 10 -

5 was treated with gp160 pulsed-DC at monthly intervals (arrows). Background lysis of target cells pulsed with control vaccinia virus expressing the  $\beta$  galactosidase gene was subtracted. Standard error of the mean never exceeded 5% of the mean.

##### 5. DETAILED DESCRIPTION OF THE INVENTION

10 Immunoglobulin or antibody molecules are polypeptides composed of heavy and light chains, which possess highly specific variable regions at their amino termini. The variable regions of heavy and light chains collectively form the unique antigen-recognition site of the immunoglobulin protein. These 15 variable regions contain determinants that can themselves be recognized as antigens by the immune system, and they are referred to as idiotypes.

B-cell malignancies (B cell lymphomas, 20 leukemias, and myelomas) are products of clonal proliferation of tumor cells synthesizing a single immunoglobulin molecule (or monoclonal antibody) with unique variable regions in the heavy and light chains. Since such tumors are monoclonal in origin, the 25 immunoglobulin expressed by all cells of a given tumor in a patient is identical, and can be distinguished from normal B cells by virtue of its unique idioype. B-cell lymphomas are tumors of mature lymphocytes, which generally express immunoglobulin on their cell 30 surface. The idotypic determinants of the surface immunoglobulin of a B-cell lymphoma can thus serve as a tumor-specific marker for the malignant clone since it is not expressed by any other tissues in the body.

Studies in animals as well as in humans have 35 demonstrated the usefulness of the immunoglobulin idioype as a tumor-specific antigen and as a target

for passive immunotherapy *in vivo* (Campbell et al., 1990, J. Immunol. 145:1029; Campbell et al., 1988, J. Immunol. 141:3227). Active immunization against 5 idiotypic determinants on malignant B-cells has produced resistance to tumor growth in several animal models of syngeneic tumors, as well as specific antitumor therapy against established tumors (Campbell et al., 1988, J. Immunol. 141:3227; George et al., 10 1988, J. Immunol. 141:2168). Moreover, preclinical studies in non-human primates have demonstrated that optimal immunization with immunoglobulin derived from human lymphomas requires conjugation of the protein to a strongly immunogenic carrier protein such as 15 keyhole-limpet hemocyanin (KLH) and emulsification in an adjuvant.

In a recent study, several lymphoma patients with minimal disease activity were repeatedly injected with idiotype protein coupled to KLH, emulsified in an 20 experimental adjuvant formulation (Kwak et al., 1992, New Eng. J. Med. 327:1209). Optimal immunization conditions required the use of both an immunogenic protein such as KLH and an adjuvant. In the absence 25 of adjuvant, negligible idiotype-specific immune responses were observed. However, several patients treated with the combination of KLH-idiotype and adjuvant demonstrated an anti-idiotypic immune response *in vitro* and two patients with measurable disease experienced objective tumor regressions. The 30 use of an immunologic adjuvant was also associated with toxicity. Furthermore, an approved human adjuvant, alum, may not be effective in inducing anti-idiotypic responses.

The present invention demonstrates that 35 patients with non-Hodgkin's, B cell lymphoma who are not eligible for bone marrow transplantation can

- 12 -

tolerate the infusion of autologous DC following *in vitro* incubation of these cells with purified immunoglobulin idiotype isolated from autologous tumor

---

source of DC in man is the peripheral blood, which contains an estimate of fewer than 1 DC per 100 white blood cells.

5           The potency of the accessory cell function of DC in antigen presentation allows for the use of these cells in relatively small numbers when enriched, and absolute purity is not necessary for the generation of a T cell response *in vivo*. However, it  
10          is most preferable that a highly purified DC population (>90%) be used for *in vivo* administration.

DC may be isolated from a normal human or from a patient suffering from a disease.

15          Additionally, such individuals may be treated with colony stimulating factors to increase their number of DC prior to isolation. For example, GM-CSF ("LEUKINE", Immunex Corporation, Seattle, WA) may be infused into an individual at 250 mcg/m<sup>2</sup>/day for several days up to three weeks intravenously prior to  
20          obtaining the peripheral blood mononuclear leukocytes (PBML) for the purification of DC. This procedure may increase the yield of DC for antigen pulsing and subsequent infusion.

Human DC may be isolated from any tissues  
25          where they reside, using a variety of separation methods. Example 6, infra, presents variants of such methods as illustrations for isolating DC from the human peripheral blood. This procedure is principally designed to avoid the exposure of DC to antigens such  
30          as fetal calf serum, sheep red blood cells and murine monoclonal antibodies which have been used in the separation of peripheral blood leukocytes. Since DC may be able to present such proteins to T cells, even in the absence of other exogenously added antigens,  
35          conventional methods of DC isolation may lead to activation of T cells not specific for the antigens of

interest, thus potentially masking the response sought. In accordance with this aspect of the invention, human PBML may be isolated from blood samples, particularly buffy coats or leukocytes prepared by apheresis, by "FICOLL HYPAQUE" gradient centrifugation followed by "PERCOLL" discontinuous centrifugation (Markowicz and Engleman, 1990, J. Clin. Invest. 85:955) followed by "METRIZAMIDE" (2-[3-  
10 Acetamido-5-N-methyl-acetamido-2,4,6-triiodobenzamido]-2-deoxy-D-glucose) or "NYCOPREP 1.068" NYCODENZ, N.N'-Bis(2,3 dihydroxypropyl)-5-[N-(2,3-dihydroxypropyl) acetamido]-2,4,6-trilodo-isophtalamide discontinuous centrifugation. The high  
15 buoyant density (HD) fraction contains  $\gamma\delta$  and  $\alpha\beta$ -T cells, B cells, and NK cells, whereas DC are in the low buoyant density (LD) fraction of the "METRIZAMIDE" or "NYCOPREP 1.068" gradient. The LD fraction can then be subjected to a second "METRIZAMIDE" or  
20 "NYCOPREP 1.068" gradient to obtain a further enriched population of DC. DC may also be further enriched using additional protocols, depending on the level of purity required. Isolated DC can be pulsed immediately with any antigen of interest.  
25 Alternatively, DC may be isolated by procedures involving repetitive density gradient centrifugation, positive selection, negative selection, or a combination thereof. However, the above-mentioned density gradient methods are preferred  
30 because they do not contain xenogeneic proteins in the form of mouse antibodies or sheep red blood cells which may be internalized and presented by DC prior to the addition of an exogenous antigen of interest. Positive selection methods may utilize affinity chromatography with antibodies directed to DC surface markers. Positive selection does not necessarily

require the use of antibodies that recognize DC-specific determinants. For example, B cells and monocytes may be depleted first from the DC-containing fraction after density gradient centrifugation, plastic adhesion, and Fc receptor panning, then an antibody to MHC-Class II antigen can be used to positively select for DC. Negative selection includes modifications of the protocol disclosed herein, supra.

10 In essence, a DC-containing cell preparation may be reacted with one or more antibodies directed at cell surface antigens not expressed by DC for the removal of non-DC. Antibodies to any T cell, B cell, monocyte, and granulocyte markers may be used.

15 Examples of such antibodies include anti-CD3, anti-CD4, anti-CD5, and anti-CD8 specific for T cells; anti-CD12, anti-CD19 and anti-CD20 specific for B cells; anti-CD14 specific for monocytes; and anti-CD16, and anti-CD56 specific for natural killer 20 cells (Becton Dickinson, San Jose, CA and Ortho Diagnostics, NJ). These antibodies may be applied in any combination repeatedly or in a sequential manner for the enrichment of DC. Upon binding to the antibodies, the cells may be removed by adsorption to 25 a solid surface coated with an anti-mouse antibody, as the majority of monoclonal antibodies directed at cell surface markers are of mouse origin, or if the antibodies are conjugated with biotin, the antibody-bound cells can be removed by an avidin or 30 streptavidin-coated surface; or if the antibodies are conjugated to magnetic beads, the cells expressing antigens recognized by the antibodies can be removed in a magnetic field (Harlow and Lane, 1988, Antibodies: A Laboratory Manual, Cold Spring Harbor 35 Laboratory Press).

5.2. USE OF DENDRITIC CELLS AS  
ANTIGEN PRESENTING CELLS

The initiation of an immune response is mediated by APC, which process complex antigens into smaller fragments by enzymatic degradation, and present them in association with MHC-encoded molecules to T cells. Although macrophages/monocytes have been studied most extensively as APC, murine DC have been shown to also possess potent accessory cell function.

10 The present invention demonstrates that DC isolated from human blood present antigens for the activation of antigen-specific T cells *in vivo*.

15 5.2.1. ANTIGENIC SYSTEMS FOR PRESENTATION BY DENDRITIC CELLS

The potent accessory cell function of DC provides for an antigen presentation system for virtually any antigenic epitopes which T and B cells are capable of recognizing through their specific receptors. Example 6, *infra*, demonstrates that human DC can present immunoglobulin idotypes as antigens to T cells *in vivo*. T cell activation is manifested by T cell proliferation in response to antigen. Example 7, *infra*, shows that similarly prepared DC can present an HIV-encoded protein to HLA-matched T cells in a recipient to induce both T cell proliferative and cytotoxic responses against HIV-infected target cells. Hence, DC are useful *in vivo* in presenting antigens encoded by infectious agents such as viruses,

20 25

30 microorganisms and their products, as well as tumor antigens expressed by cancer cells (Urban and Schreiber, 1992, *Ann. Rev. Immunol.* 10: 617-644).

Infectious agents against which the present invention may be applicable include, but are not limited to, bacteria, parasites, fungi, and viruses. The multitudes of antigens encoded by these agents,

which may be processed and presented by DC include but  
are not limited to, external surface proteins, and  
structural proteins including internal enzymes. For  
5 example, antigens encoded by any genes of the HIV  
genome including the *env*, *gag*, *pol*, *nef*, *vif*, *rev*, and  
*tat* genes may all be presented by DC *in vivo*. In  
addition, peptide fragments which are degradative  
products of proteins within DC may also be directly  
10 added to DC during pulsing. A variety of other  
infectious agents including hepatitis B virus,  
hepatitis C virus, cytomegalovirus, herpes simplex  
virus, varicella zoster, Staphylococcal species and  
Mycobacterium species are encompassed within the scope  
15 of the invention.

In addition to immunoglobulin idiotypes as  
tumor-specific antigens, a large number of human  
tumor-associated antigens have been identified by  
monoclonal antibodies (Reisfeld and Cheresh, 1987,  
20 *Adv. Immunol.* 40: 323-377). Although these cellular  
antigens are selectively expressed in higher  
quantities by certain tumor cells, it has not been  
established that they naturally elicit an immune  
response in cancer patients or can be used effectively  
25 to induce such a response. Unlike animal tumor models  
in which tumor-reactive T and B cells can be induced  
through hyperimmunization with tumor cells or tumor  
antigens, intact human tumor cells or oncogenic  
proteins may not be easily tested in humans without an  
30 approved clinical protocol. Thus, most human studies  
have utilized lymphocytes obtained from cancer  
patients whose cells presumably have been exposed to  
antigens expressed by their autologous tumor cells *in*  
*vivo*. However, it has been shown in some systems that  
35 tumor development is accompanied by a down-regulation  
of tumor specific immune responsiveness mediated by

suppressor cells, and if so, T cells isolated from cancer patients may have already come under the influence of such suppression *in vivo* so as to not 5 function in a manner similar to that of T cells obtained from tumor-immune hosts. Moreover, these attempts to activate human tumor-reactive T cells have generally used monocytes as APC, which have been shown to be much less effective than DC, especially if the T 10 cells have not been primed adequately *in vivo* against the tumor antigens.

The antigen-pulsed DC described herein may be used as a cellular adjuvant for presenting tumor antigens *in vivo*. The potent accessory cell function 15 of DC can present tumor antigens to T cells of cancer patients *in vivo*, whose immune response is apparently inadequate to eliminate the tumors *in vivo*. Whole tumor cells in viable or irradiated form, tumor membrane preparations, and tumor antigens purified 20 from natural sources or expressed as recombinant products or chemically synthesized as peptides may be used to pulse DC *in vitro*.

Recently, oncogene products have been shown to be capable of inducing murine T cell activities. 25 For example, oncogenic forms of the ras gene product p21, and the fusion product p210 of the bcr-abl gene induce T cell proliferative responses, when used to immunize mice (Peace et al., 1991, J. Immunol. 146: 2059-2065; Chen et al., 1992, Proc. Natl. Acad. Sci. 30 USA 89: 1468-1472). Thus, oncogenic proteins which are different from their normal cellular counterparts as a result of amino acid substitutions may possess new immunogenic determinants that are recognizable by T cells. It is not necessary that such proteins be 35 expressed naturally on the cell surface, as cytoplasmic and nuclear proteins may be processed,

attached to MHC-encoded products intracellularly, and translocated to the cell surface in a complex form (Gould et al., 1989, J. Exp. Med. 170: 1051-1056).

5 Since oncogene products are expressed in a variety of tumor types including colon cancer, leukemia and lymphoma, antigen-pulsed DC may be used to activate T cells *in vivo* against such cancers. Other molecules which are associated with various types of cancer are

10 also encompassed by the present invention, and they include, but are not limited to, HER-2/neu gene product (United States Patent No. 4,968,603), estrogen receptor, milk fat globulin, p53 tumor suppressor protein (Levine, 1993, Annu. Rev. Biochem. 62:623),

15 mucin (Taylor-Papadimitriou, 1990, International Publication No. WO90/05142), telomerases, nuclear matrix proteins, MART-1, MAGE-1, MAGE-2, MAGE-3 (van der Bruggen et al., 1991, Science 254:1643; Celis et al., 1994, Proc. Natl. Acad. Sci. USA 91:2105), GP100

20 (Bakker et al., 1994, J. Exp. Med. 179:1005), prostatic acid phosphatase, carcinoembryonic antigen, tyrosinase and papilloma viral antigens.

Bacterial, parasitic, fungal, viral, and tumor antigens of cellular or viral origin may be

25 introduced to DC by addition to DC cultures followed by incubation, by the osmotic lysis of pinosomes after pinocytotic uptake (Moore et al., 1988, Cell 54: 777-785), or by uptake in antigen-containing liposomes. Antigens may be used as purified naturally occurring

30 whole polypeptides, purified recombinant whole polypeptides, whole organisms or cells in viable or dead forms, protein fragments generated by enzymatic digestion, or synthetic peptides produced by solid phase chemical methods (Creighton, 1983, Protein Structures and Molecular Principles, W.H. Freeman and Co., N.Y. pp 50-60). The amount of antigens necessary

for pulsing DC may vary depending on the nature, size, and purity of the molecules. In general, polypeptides may be used at 1-100 µg/ml, and small peptides at 1-50  
5 µg/ml. Introduction by osmotic lysis of pinosomes requires larger amounts of proteins in the range of 200-500 µg/10<sup>6</sup> APC. Alternatively, exogenous genes encoding specific antigens of interest or expression vectors containing such genes or portions thereof may  
10 be incorporated into DC in expression vectors using conventional methods, including transfection, recombinant vaccinia viruses and retroviruses (Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory  
15 Press). This approach causes the continual expression of integrated genes, leading to MHC occupancy by the gene products. Any of the aforementioned methods for introducing exogenous antigens into DC as well as any others commonly used by those skilled in the art are  
20 hereinafter collectively referred to as antigen pulsing of DC.

#### 5.2.2. INDUCTION OF PRIMARY AND SECONDARY T CELL RESPONSES IN VIVO

The present invention relates to a method of activating an immune response in a human patient to an antigen. The method includes the isolation of human DC, preferably from the peripheral blood, pulsing the cells with an antigen *in vitro*, and then administering  
25 the antigen-pulsed cells into a patient whose cells or tissues express the antigen.  
30

The ability of DC to process and retain antigenic fragments for several days permits their use as potent immunogens *in vivo*. DC may be pulsed with antigens according to the various methods described in  
35 Section 5.2.1, *supra*, washed, and administered *in vivo* as vaccines and/or immunotherapeutics for the

elicitation or augmentation of a pre-existing but weak T cell response. In an effort to increase the number of isolated DC for antigen pulsing and subsequent *in vivo* administration, the isolated cells may be first expanded in number prior to incubation with antigens. It has been shown that GM-CSF and tumor necrosis factor- $\alpha$  induce the differentiation of human hematopoietic progenitor cells into DC (Caux et al., 1992, *Nature* 360:258). Thus, isolated DC may be expanded by treatment with such cytokines in culture.

Immunization with antigen-pulsed DC may increase both the magnitude and the specificity of a response. It may be desirable to repeat such immunizations at time intervals of days or weeks. The potency of DC as APC may alleviate the need of using conventional adjuvants to augment the response, although it does not preclude the use of adjuvants to further enhance immune reactivity. In addition, the antigen-pulsed DC may be administered in combination with cytokines that can maintain their number and activity for prolonged periods *in vivo*. Such cytokines include colony stimulating factors such as GM-CSF and interleukins such as IL-12.

The antigen-pulsed DC may be suspended in any known physiologic saline at a concentration sufficient to induce an immune response as detected by assays which measure T cell proliferation, T cell cytotoxicity, antibody production or reduction of the number of antigen-positive cells or tissues. A patient usually receives the total number of isolated DC pulsed with antigen. Depending on the yield of DC following each isolation procedure, a patient may be infused with several million up to several hundred million DC. The cells may be infused into autologous,

HLA-matched allogeneic or even HLA-mismatched  
allogeneic patients.

5           6. EXAMPLE: B-CELL LYMPHOMA REDUCTION  
INDUCED BY AUTOLOGOUS  
IMMUNOGLOBULIN IDIOTYPE-PULSED  
HUMAN DENDRITIC CELLS

10           6.1. MATERIALS AND METHODS

10           6.1.1. CELL SEPARATION  
Human DC were obtained from buffy coats of  
lymphoma patients after leukapheresis. PBML were  
isolated by "FICOLL-HYPAQUE" gradient centrifugation  
15          (Boyum, 1968, Scand. J. Clin. Lab. Invest: 21:21-29).  
In brief, a buffy coat was diluted with Dulbecco's PBS  
without divalent ions such as Ca<sup>2+</sup> or Mg<sup>2+</sup> (referred to  
as DPBS) up to 10 ml. 10 ml of "FICOLL" was gently  
underlaid into each tube and centrifuged at 1000 x g  
20          for 35 minutes at room temperature. The interface was  
collected and washed with DPBS three times.

25          To further separate various cell populations  
from the remaining mononuclear cell fraction, the  
preparation was further fractionated over a four layer  
discontinuous "PERCOLL" gradient (30%, 40%, 50.5% and  
75%) (Pharmacia, Uppsala, Sweden) (Markowicz and  
Engleman, 1990, J. Clin. Invest. 85:955). Original  
"PERCOLL" density was prepared at 1.130g/ml DPBS and  
15 ml of a 50.5% "PERCOLL" solution was made and  
30          shaken in a conical polypropylene tube to create a  
foam on a surface of the "PERCOLL" solution. The tube  
was gently underlaid with about 6.5 ml of 75%  
"PERCOLL". The tube was then slowly overlaid with 3  
to 3.5 ml of 40% "PERCOLL" dropwise along the side of  
35          the tube which was being slowly rotated, followed by  
an overlay of 2.5ml of 30% "PERCOLL" in the same

manner. The gradients were kept on ice for use within about 4 hours.

2.5-3x10<sup>8</sup> PBML in 5 to 10 ml of DPBS  
5 supplemented with 5% human serum were overlaid onto the four layer discontinuous "PERCOLL" gradient. Human serum was negative in licensed blood bank screening assays for antibodies to HIV, HTLV, hepatitis viruses, and treponema pallidum. The serum  
10 was heat inactivated at 56°C for 1 hour and filtered through 0.2 µm filter prior to use. The cells were centrifuged at 1000 x g for 20-25 minutes at 4°C. The LD cells (monocytes) were collected from the interface over the "PERCOLL" 50.5% layer, whereas the  
15 lymphocytes and DC were collected from the interface between 75% and 50.5% layers. The collected cell fractions were diluted with DPBS at least 3 volumes and centrifuged at 1000 x g for 12 minutes at 4°C. The cells were washed twice with DPBS supplemented  
20 with 5% human serum at 400 x g for 5-6 minutes at 4°C.

The HD cells (3-7 x 10<sup>8</sup>/50 ml of RPMI containing 10% pooled human serum) were then cultured overnight in teflon vessels at 37°C. Thereafter, the cultured cells were subjected to gradient  
25 centrifugation in "METRIZAMIDE" (15.5%) by overlaying the cells onto 10 ml of 15.5% (wt/vol) "METRIZAMIDE" (Sigma Chemical Co.) followed by centrifugation at 650 xg for 10 min at room temperature. This fraction was further depleted of contaminating monocytes by a solid  
30 phase absorption procedure for about 20 min. on human IgG-coated petri dishes. The IgG was commercial preparation tested and approved for intravenous human use. The DC were then enriched over a second "METRIZAMIDE" gradient (14%). The HD cells from the  
35 first "METRIZAMIDE" gradient consisted of a mixture of

$\alpha\beta$  and  $\gamma\delta$ -T cells, B cells, and NK cells. The purity of the DC obtained using this procedure were 60-90%.

Alternatively, the DC could be enriched  
5 after overnight culture by centrifugation over a "NYCOPREP 1.068" discontinuous gradient (Nycomed Pharma AS, Oslo, Norway). About  $2.5 \times 10^8$  cells were suspended in 15-20 ml of a solution made up of 85% DPBS, 10% human serum and 5% EDTA. This was underlaid  
10 sequentially with 4-5 ml of a solution of 50% human serum, 10% EDTA and 10% DPBS, followed by 4 ml of a solution of 75% "NYCOPREP 1.068", 24% DPBS and 1% human serum, followed by 8 ml of 100% "NYCOPREP 1.068". The cells were centrifuged at 400 xg for 13  
15 minutes at room temperature. The interface and the pellet were collected and diluted with at least 3 volumes of DPBS containing 10% human serum, and centrifuged at 800 x g for 12 minutes at 20°C. The cells were washed twice with 10% human serum in RPMI  
20 at room temperature, and DC occupied 30-40% of the total cell population. However, these cells could be further enriched by another round of "NYCOPREP" centrifugation to obtain a LD fraction of 80-90% DC.  
Alternatively, the LD cells after the first "NYCOPREP"  
25 step could be negatively selected by incubation with antibody-coated petri dishes to remove CD3<sup>+</sup>, CD14<sup>+</sup>, CD16<sup>+</sup> and CD20<sup>+</sup> cells. The non-adherent cell population also contained 80-90% DC. However, density gradient centrifugation was preferred in order to  
30 avoid the use of xenogeneic proteins in the form of antibodies against leukocyte markers. All procedures described herein could produce a yield of  $1-2.5 \times 10^6$  cells from 400-500 ml of whole blood.

The purity of DC following each step of DC  
35 enrichment was assessed by staining with an anti-HLA-DR (anti-MHC class II) antibody (CA141)

conjugated to fluorescein, and phycoerythrin-conjugated anti-CD14 (anti-monocyte).

5 Cytofluorographic analysis of the entire cell population was assessed by Fluorescence Activated Cell Sorter. HLA-DR<sup>+</sup> but CD14<sup>-</sup> cells represented the DC population.

#### 6.1.2. TUMOR IMMUNOGLOBULIN IDIOTYPE PRODUCTION

10 All patients had a histopathological diagnosis of non-Hodgkin's lymphoma. Immunophenotypic studies of the tumors showed that they were of B-cell origin, with the surface expression of immunoglobulin molecules composed of both heavy and light chains in a 15 monotypic pattern. Patients were selected who had low grade B cell lymphoma and were not eligible for bone marrow transplantation. The base-line studies used to evaluate clinical disease in all patients included complete physical examination, chest radiography, 20 routine blood counts and chemistry tests, abdominal and pelvic CT scanning, with or without bipedal lymphangiography, which were all normally part of routine clinical care of such patients. All underwent 25 re-staging during the course of the study according to the objective procedures used at base line.

In order to cause the B cell lymphoma to secrete their immunoglobulin for purification for use as antigens, a cell suspension obtained from the tumor biopsy specimen was washed in phosphate buffered 30 saline (PBS) and mixed with the HAT sensitive heterohybridoma B5/K6H6 (B5) in a ratio of 1:4 or 1:5 (fusion partner:tumor cells). B5 is a heterohybridoma that was produced by the fusion of the NS-1 mouse myeloma fusion partner with a human lymphoma cell. 35 The B5 clone has lost the ability to spontaneously secrete immunoglobulin. A subclone was identified

which had retained the ability to secrete immunoglobulin when fused with human B-cells. This subclone was drug-marked so that it would not survive 5 in HAT medium. Studies by Carroll et al. (1986, J. Immunol. Methods 89:61) show B5 to be a useful fusion partner for rescuing idiotype secretion from non-secreting human B-cell tumors. No mouse immunoglobulin is produced by B5 or hybridomas derived 10 from it.

The mixture of tumor cells and fusion partner cells was washed 2 times in Hank's balanced salt solution (HBSS). Supernatant was aspirated and the cell pellet was exposed to 40% polyethylene glycol 15 (PEG) for 2 minutes. The PEG was diluted slowly by adding HBSS, and the cells were centrifuged. The cells were then resuspended in complete medium (RPMI Medium, 10% fetal bovine serum, glutamine 4 mM) to density of  $2 \times 10^6$  cells per ml, and 0.1 ml was then 20 added to the wells of a microtiter plate. Twenty-four hours later after the cells had recovered from the PEG fusion, selection for rescue fusions was begun by changing the media to HAT media (complete media with the addition of hypoxanthine  $10^{-4}$  M, thymidine  $1.6 \times 10^{-3}$  M and aminopterin  $4 \times 10^{-5}$  M). The microtiter 25 plates containing the cells were incubated for 10-20 days at  $37^\circ\text{C}$  in a humidified 5% CO<sub>2</sub> in air incubator. The supernatants were removed from the wells and the cells were fed with the medium described above but 30 without the aminopterin (HT medium).

An ELISA assay was used to determine which wells of the microtiter plate contained hybridomas which were secreting the rescued tumor immunoglobulin. The tumor biopsy specimen used for cell fusion 35 contained a large predominance of malignant cells which expressed a single light chain type, either

kappa or lambda. Wells secreting immunoglobulin with the heavy and light chain type corresponding to the known immunophenotype of the tumor specimen were  
5 selected and expanded.

Goat anti-human Ig heavy chain-specific reagents were diluted in 0.05 M sodium bicarbonate buffer (pH 9.5). The 96-well microtiter plates were coated with this antibody in a volume of 50  
10 microliters per well. The plates were incubated overnight at 4°C. The plates were then washed 5 times with normal saline containing 0.05% Triton X (wash buffer). Nonspecific binding was blocked by incubating the wells with 5% non-fat milk in PBS for 1  
15 hour and then washing 5 times with wash buffer. Hybridoma supernatants were added (50 microliters per well) and incubated for 1 hour at room temperature. The plates were again washed and developed with 50 microliters per well of horseradish peroxidase  
20 conjugated to goat anti-human Ig light chain-specific reagents. The plates were incubated for 60 minutes at room temperature. Antibody reactivity was determined by added ABTS substrate and the optic density was read at 405 nm using a microtiter plate reader.

As the hybridomas were grown, the supernatants were tested for immunoglobulin content using the ELISA described above. Dilutions of the supernatants were compared to a standard curve generated by using purified human immunoglobulin of  
25 the same isotype as that expressed on the patient's tumor. The idiotype protein was confirmed to be derived from the patient's lymphoma by cloning and comparing the DNA sequences of the variable region genes from both the lymphoma and rescue fusion.  
30 Hybridomas that constantly produced in excess of 2 micrograms per ml were expanded to large volumes

(2000-5000 ml). The cell density was allowed to increase until the media was fully spent and the supernatants were collected and pooled.

5       The rescued tumor idiotype protein was purified from bulk supernatant using affinity chromatography. For IgM class, a murine monoclonal anti-human IgM heavy chain-specific antibody was coupled to cyanogen bromide activated sepharose B4 or  
10      an equivalent solid phase matrix at a concentration of 2-6 mg/ml of swollen beads (immunoadsorbent). Rescued tumor idiotypes of the IgA class was purified using an immunoadsorbent column consisting of a goat or rabbit anti-human IgA-specific antibody similarly coupled to  
15      a solid phase matrix. Idiotypes of the IgG class were purified using a column of protein A coupled to a solid phase. The idiotype-containing supernatant was gravity flowed through the immunoadsorbent column.  
After absorption, the column was washed with 200 ml of  
20      physiologic saline to remove the unbound protein. The idiotype was eluted with 0.1 M glycine-HCl buffer (pH 2.4) using absorption at 280 nm to monitor the protein effluent. The protein peak was collected and the immunoglobulin level measured using an ELISA technique  
25      or absorption at 280 nm. The protein purity was determined by SDS-PAGE.

#### 6.1.3. PREPARATION OF ANTIGENS

##### Keyhole Limpet Hemocyanin *Megathura*

30      *crenulata* (KLH) was obtained from Calbiochem, San Diego, California (Cat. #374805). The KLH was supplied in a form containing more than 60% protein in BES buffer and magnesium sulfate. The protein purity, which was determined by the vendor, was greater than  
35      90%.

Prior to use, the KLH was dialyzed extensively against physiologic saline and then passed through a detoxigel column (Pierce Chemical Company, 5 Rockford, Illinois, Cat. #20339) in PBS pH 7.4 or it was passed over a QAE Zeta Prep 15 disk (LKBm, Bromma, Sweden, Cat. #224-202) using 25 mM Tris-HCl pH 8.0. A gradient of sodium chloride was used to remove the endotoxin which adhered to the column. Repeated 10 passage of the KLH over the columns reduced the endotoxin to an acceptable level. The limulus amoebocyte lysate (LAL) assay was used to monitor endotoxin levels.

Purified idiotype specific protein and KLH 15 were then dialyzed extensively against sterile physiologic saline. Each product was then concentrated or diluted to achieve a final concentration of 1 mg/ml in sodium chloride. The proteins were then sterile filtered through 0.45  $\mu\text{m}$  20 filters. The final concentration was determined by measuring the absorption at 280 nm or performing an ELISA on a small, expendable aliquot of the final product. The final product was aseptically filled into sterile containers under a laminar flow hood. 25 The vials were then frozen and stored at -20 C until needed. Sterility of the final product was confirmed by a standard 5-day bacterial culture assay performed by clinical laboratory.

30           **6.1.4. PULSING OF DENDRITIC  
                CELLS WITH ANTIGENS**

Enriched DC were resuspended in RPMI media at a concentration of approximately one million 35 cells/ml. The DC were split into two independent cultures of five million cells into 24 well plates. Each set of DC was then cultured with either sterile, purified idiotype immunoglobulin protein or KLH at a

- 30 -

concentration of fifty micrograms/ml for 4-5 hours or overnight in a humidified 37° C incubator with 5% CO<sub>2</sub>.

5           **6.1.5. INJECTION OF ANTIGEN-PULSED DENDRITIC CELLS**

DC pulsed with either idiotype protein or KLH were washed three times in physiologic, pyrogen-free, injection grade saline and resuspended into a volume of 100 ml in an intravenous injection  
10 administration bag. For each infusion, the patients received the total number of DC isolated from their own blood. Since each isolation yielded a different number of DC, each cell infusion contained between 5x10<sup>6</sup> to 100x10<sup>6</sup> antigen-pulsed DC. The patients were  
15 premedicated with acetaminophen and diphenhydramine, and received the transfusion of DC through a peripheral intravenous line or a central catheter (if available) over a period of 30-60 minutes. Vital signs were monitored continuously prior to and during  
20 the infusion. All therapy was monitored and supervised closely by a physician. Patients received similarly prepared antigen-pulsed DC for up to four times.

25           Any systemic reactions to the procedure were carefully noted. Systemic reactions were scored for temperature, blood pressure, and signs of bronchospasm, vasculitis, and/or immune complex formation. The risk of anaphylaxis was extremely low with the use of autologous cells.  
30

6.1.6. ASSAY FOR IDIOTYPE-SPECIFIC PROLIFERATIVE RESPONSE

Proliferation assays were adapted from the techniques of Chain et al. (1987, J. Immunol. Methods  
35 99:221). Fresh PBML, prepared by "FICOLL-HYPAQUE" gradient centrifugation, were washed and plated at a

concentration of  $4 \times 10^5$  cells per well in Iscove's modified Dulbecco's medium (IMDM) with 1 percent human AB serum (IMDM-1% AB). KLH or autologous 5 immunoglobulin idioype at concentrations of 0 to 100  $\mu\text{g}$  per milliliter in IMDM-1% AB preparation was added in quadruplicate. After 3 days, the cells were divided and fed with IMDM containing 5% FCS and 30 units/ml of IL-2. After the cells were incubated for 10 a total of five days at 37°C in an atmosphere containing 5% carbon dioxide, they were pulsed for 16 to 20 hours with  $^3\text{H}$ -labeled thymidine (1  $\mu\text{Ci}$  per well). Data are expressed as mean counts per minute of  $[^3\text{H}]$  thymidine incorporation minus background.

15

#### 6.1.7. ASSAY FOR ANTI-IDIOTYPIC ANTIBODIES

Microtiter plates were coated either with idioype protein or with a panel of other immunoglobulins of the same isotype. Patient serum 20 was serially diluted. Pretreatment samples were used as a negative control. Binding of antibodies in the patient's serum to the test panel of immunoglobulins including the patient's idioype was detected by goat anti-human light chain-HRP antibodies specific for the 25 light chain opposite to the patient's idioype or by a mixture of anti-human heavy chain isotype-specific-HRP antibodies that did not react with the patient's idioype.

30

#### 6.2. EXAMPLE

Four patients with follicular B cell lymphoma received a series of three or four infusions of immunoglobulin-pulsed DC. One patient entered the study with active disease manifested by easily 35 discernible tumor masses on the x-ray computed tomography of the chest and abdomen. After providing

informed consent the patient underwent leukapheresis at the Stanford University Blood Center on three occasions at four-week intervals. DC were isolated 5 after each leukapheresis and equal aliquots ( $5 \times 10^7$  cells) were cultured overnight with either KLH or immunoglobulin idiotype which had been isolated from the patient's own tumor. The antigen-pulsed DC were extensively washed to remove any free immunoglobulin, 10 suspended in isotonic saline and infused intravenously. Two weeks after each infusion, the patient received 0.5 mg of soluble idiotype protein in sterile physiologic saline subcutaneously as a boost, and a separate 0.5 mg boost of sterile KLH at a 15 separate subcutaneous site. The cell infusions and boosts were well tolerated and two weeks following each infusion fresh lymphocytes isolated from peripheral blood were challenged *in vitro* with graded doses of either KLH or idiotype, and their 20 proliferative activity was assayed.

Prior to DC infusion, the patient failed to respond to either KLH or immunoglobulin idiotype; however, following DC infusion the patient's lymphocytes proliferated in response to both KLH and 25 idiotype. As shown in FIG. 1, there was little or no response to these antigens prior to the infusion of antigen-pulsed DC, there were significant proliferative responses following the initial infusion, and the responses increased following the 30 third infusion. Most importantly, the patient's tumor burden, which had been increasing for more than one year prior to infusion of DC was reduced by more than 50% when measured after the third infusion of antigen-pulsed DC and by 100% after the fourth treatment 35 (FIG. 2A-D). To date, this patient is in a clinical complete remission. In addition, when PBML of this

patient were expanded in culture in the presence of the immunoglobulin, the cells were able to lyse autologous tumor hybridomas in chromium release assays, indicating the development of tumor-specific CTL in this patient.

The second patient had residual lymphoma in periaortic and parailiac regions prior to DC infusion. Despite a measurable anti-idiotypic proliferative response, this patient subsequently developed progressive disease four months after the primary series of infusions. Following a fourth immunization, the patient has remained stable and has not required further therapy.

The third patient had equivocal radiographic findings of tumors, but showed evidence of disease in bone marrow and blood by the use of a sensitive assay involving polymerase-chain reaction for detecting tumor-specific immunoglobulin heavy chain gene rearrangement. The sensitivity of this technique allowed the detection of one tumor cell in  $10^7$  normal PBML. After completion of the first three immunizations, tumor was no longer detectable in biopsy samples by molecular analysis.

The fourth patient had stage IV A follicular lymphoma with growing disease prior to DC therapy. This patient completed three cell infusions and has shown a minor response with regression of some peripheral lymph nodes. Furthermore, all patients developed tumor idiotype-specific proliferative responses during the course of DC infusion.

These results demonstrate the feasibility and safety of isolating DC, pulsing them with a tumor antigen, and infusing the cells into autologous patients at repeated intervals. They further suggest

that such infusions are associated with the induction of clinically significant immune responses.

5           7. EXAMPLE: HIV-SPECIFIC T CELL RESPONSES  
INDUCED BY HIV ENVELOPE  
ANTIGEN-PULSED HUMAN  
DENDRITIC CELLS

10           7.1. MATERIALS AND METHODS

15           7.1.1. DENDRITIC CELL PREPARATION AND  
ANTIGEN PULSING

DC were enriched from the buffy coat of leukapheresed blood according to the procedure described in Section 6.1.1, *supra*. However, when the 15 HIV envelope antigen, gp160, was used to pulse DC, the cells were incubated with recombinant protein for three times. Firstly, the cells obtained after "PERCOLL" centrifugation were incubated in the teflon vessels at  $10^7$  cells/ml with 2 $\mu$ g/ml of HIV recombinant 20 gp160 (Immuno AG, Vienna, Austria) at 37°C overnight. Thereafter, DC were further enriched by "METRIZAMIDE" 25 centrifugation as described in Section 6.1.1, *supra*. Then, 10-20X10 $^6$  cells/ml were resuspended in RPMI/10% human serum plus 2  $\mu$ g/ml of the same gp160 antigen, and placed into teflon vessels at 37°C for 14-18 hours. Following incubation, the cells were washed by 30 centrifugation in DPBS/5% human serum at room temperature for 10 minutes at 500xg. The pellet was resuspended in 15 ml of the same buffer and cell clusters allowed to disaggregate at room temperature for 15 min. The cells were then underlaid with 15 ml of 14% "METRIZAMIDE"/RPMI/10% human serum, centrifuged and washed three times in RPMI/10% human serum. About 35 10 $^6$  cells were removed for phenotype analysis. Prior to infusion of antigen-pulsed DC *in vivo*, 10-20X10 $^6$

- 35 -

cells/ml in RPMI/10% human serum were again incubated with 50 µg/ml of gp160 in teflon vessels overnight.

In cases where DC were pulsed with HIV peptides, the cells were pulsed at a concentration of 5µg of peptides with 10<sup>6</sup> cells/ml. Also, only one pulsing step was used for peptides, which were presumed to not require further processing. Several HLA-A2.1-restricted HIV-1 peptides were used. The amino acid sequences, HLA binding affinities and CTL-inducing activities of these peptides are given in Table 1 below.

15

20

25

30

35

Table 1

		Amino Acid Sequence	Residues	HLA 2.1 Affinity*	Conservancy	CTL activity**
5	Env	KLTPLCVTL	120-128	0.16	97%	+
		SLLNATDIAV	814-823	0.11	57%	+
	Gag	SLYNTVATL	77-85	+++	64%	+
10	Pol	VLAEAMSQV	362-370	0.11	96%	+
		LLWKGEGAVV	956-964	0.04	100%	+
		ILKEPVHGV	464-472	0.02	92%	+

\* Ratio to IC<sub>50</sub> Standard Peptide

\*\* CTL actively demonstrated against peptide-coated target cells

### 7.2. CELL PREPARATION FOR INFUSION

After the final antigen pulsing step, the enriched DC preparation was collected the next morning and centrifuged at room temperature for 10 minutes at 500 xg. The pellet was resuspended in DPBS and cell viability was examined by trypan blue exclusion. After two additional washing steps, the cells were placed into a 100 ml injection grade saline administration bag. Using a 10ml syringe and a 19 gauge needle, 8-10ml of saline was removed from the bag for use in resuspending the cell pellet. Thereafter, the cell suspension was brought up into the syringe and injected into the bag, followed by injection of 5 ml of previously frozen autologous serum.

### 7.3. EXAMPLE

Asymptomatic HIV-seropositive patients generally exhibit a vigorous T cell response against HIV. However, such a response subsides as clinical symptoms of the disease begin to develop. In order to augment the T cell immunity against HIV, an HIV-seropositive patient was infused with DC prepared from

an HLA-matched sibling that had been pulsed with HIV gp160 in vitro.

Donor DC cells were enriched from peripheral blood and pulsed with HIV-encoded gp160 and administered into the patient three times at one month intervals. During the course of treatment, PBML were obtained from the patient and assayed for T cell proliferative and cytotoxic responses against HIV-infected cells. FIG. 3 demonstrates that shortly after the first cell infusion, T cells obtained from the patient proliferated in response to HIV gp160 in culture. The T cell proliferative activity continued to rise for two weeks and was maintained at the same level for over six weeks after the first infusion.

Additionally, T cells obtained from the same patient also exhibited HIV-specific CTL (FIG. 4). Therefore, the administration of HIV antigen-pulsed DC induced both HIV-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells. Since a delay of clinical symptoms of HIV correlates with a detectable HIV-specific T cell response in an HIV-infected individual, an augmentation of such T cell responses will likely contribute to the control of the spread of HIV, thereby delaying HIV clinical latency, and prolonging of survival of infected individuals.

The present invention is not to be limited in scope by the exemplified embodiments, which are intended as illustrations of individual aspects of the invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

All publications cited herein are incorporated by reference in their entirety.

WHAT IS CLAIMED IS:

1. A method of activating an immune response in a  
5 human patient to an antigen comprising:
  - (a) isolating human dendritic cells;
  - (b) pulsing the cells with an antigen; and
  - (c) administering the cells pulsed with the antigen into the human patient.
- 10 2. The method of Claim 1 in which the dendritic cells are isolated from human peripheral blood.
- 15 3. The method of Claim 1 in which the immune response is mediated by T cells.
4. The method of Claim 1 in which the immune response is mediated by B cells or their secreted antibodies.
- 20 5. The method of Claim 1 in which the antigen is produced by tumor cells.
6. The method of Claim 5 in which the antigen is  
25 produced by B-cell tumor cells.
7. The method of Claim 6 in which the antigen is an immunoglobulin.
- 30 8. The method of Claim 1 in which the antigen is a whole microorganism.
9. The method of Claim 1 in which the antigen is a virus.

10. The method of Claim 1 in which the antigen is a polypeptide.
- 5 11. The method of Claim 10 in which the polypeptide is gp160 encoded by HIV.
12. The method of Claim 1 in which the antigen is a peptide.
- 10 13. A pharmaceutical composition comprising isolated human dendritic cells which have been pulsed with an antigen *in vitro*.
- 15 14. The pharmaceutical composition of Claim 13 in which the dendritic cells are isolated from human peripheral blood.
- 20 15. The pharmaceutical composition of Claim 13 in which the antigen is produced by tumor cells.
16. The pharmaceutical composition of Claim 15 in which the antigen is produced by B-cell tumor cells.
- 25 17. The pharmaceutical composition of Claim 16 in which the antigen is an immunoglobulin.
- 30 18. The pharmaceutical composition of Claim 13 in which the antigen is a microorganism.
19. The pharmaceutical composition of Claim 13 in which the antigen is a virus.
- 35 20. The pharmaceutical composition of Claim 13 in which the antigen is a polypeptide.

- 40 -

21. The pharmaceutical composition of Claim 20 in which the polypeptide is gp160 encoded by HIV.
- 5 22. The pharmaceutical composition of Claim 13 in which the antigen is a peptide.
- 10 23. A method for treating cancer in a human cancer patient, comprising:
  - (a) isolating human dendritic cells;
  - (b) pulsing the cells with an antigen produced by cancer cells; and
  - (c) administering the cells pulsed with the antigen into the human patient having the cancer cells.
- 15 24. The method of claim 23 in which the cancer cells are lymphoma cells.


20

25

30

35

1/4



2/4




FIG.2A




FIG.2B

SUBSTITUTE SHEET (RULE 26)

3/4




FIG.2C




FIG.2D

SUBSTITUTE SHEET (RULE 26)




FIG. 3




FIG. 4

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/19954**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) :A61K 35/14, 39/02, 39/12, 39/385, 39/395; C12N 5/08; G01N 33/554

US CL :424/93.1, 93.3, 93.4, 93.6, 93.7; 435/2, 7.24, 240.2; 436/519

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/93.1, 93.21, 93.3, 93.4, 93.6, 93.7, 93.71; 435/2, 7.24, 240.2; 436/519; 530/810

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 91/13632 A1 (THE IMMUNE RESPONSE CORPORATION) 19 September 1991, see entire document.	1,3-7,10, 12-13, 15-17,20, 22-24
-----		-----
Y		2, 14
X,P	WO 95/34638 A1 (THE BOARD OF TRUSTEES OF LELAND STANFORD JUNIOR UNIVERSITY) 21 December 1995, see entire document.	1-10,12-20, 22-24
X,P	HSU et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Medicine. January 1996, Vol. 2, No. 1, pages 52-58, see entire document.	1-7,10, 12-17,20, 22-24

 Further documents are listed in the continuation of Box C. See patent family annex.

- \* Special categories of cited documents:
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reasons (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed
- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search  
03 MARCH 1997

Date of mailing of the international search report

26 MAR 1997

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231  
Facsimile No. (703) 305-3230Authorized Officer  
JAMES L. GRUN, PH.D.  
Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No. PCT/US96/19954
---

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	SORNASSE et al. Antigen-pulsed dendritic cells can efficiently induce an antibody response in vivo. Journal of Experimental Medicine. January 1992, Vol. 175, pages 15-21, see entire document.	1-24
Y	INABA et al. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. Journal of Experimental Medicine. August 1990, Vol. 172, pages 631-640, see entire document.	1-24
Y	INABA et al. Dendritic cells as antigen presenting cells in vivo. Intern. Rev. Immunol. 1990, Vol. 6, pages 197-206, see entire document.	1-24
X	MACATONIA et al. Primary stimulation by dendritic cells induces antiviral proliferative and cytotoxic T cell responses in vitro. Journal of Experimental Medicine. April 1989, Vol. 169, pages 1255-1264, especially page 1262.	13-14, 18-19 -----
Y	MACATONIA et al. Suppression of immune responses by dendritic cells infected with HIV. Immunology. 1989, Vol. 67, pages 285-289, see entire document.	1-12
A	MACATONIA et al. Dendritic cell infection, depletion and dysfunction in HIV-infected individuals. Immunology. 1990, Vol. 71, pages 38-45, see entire document.	1-24
X	MACATONIA et al. Primary proliferative and cytotoxic T-cell responses to HIV induced in vitro by human dendritic cells. Immunology. 1991, Vol. 74, pages 399-406, see entire document, especially page 401.	13-15, 18-22 -----
Y	MARKOWICZ et al. Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. J. Clin. Investigation. March 1990, Vol. 85, pages 955-961, see entire document.	1-24
X	BHARDWAJ et al. Dendritic cells are potent antigen-presenting cells for microbial superantigens. Journal of Experimental Medicine. January 1992, Vol. 175, pages 267-273, especially page 270.	13-14, 20, 22
X	PANCHOLI et al. Dendritic cells efficiently immunoselect mycobacterial-reactive T cells in human blood, including clonable antigen-reactive precursors. Immunology. 1992, Vol. 76, pages 217-224, see entire document.	13-14, 18 -----
Y		1-24

## INTERNATIONAL SEARCH REPORT

International application No. PCT/US96/19954
---

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	KWAK et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idioype expressed by their tumors. New England Journal of Medicine. 22 October 1992, Vol. 327, No. 17, pages 1209-1215, see entire document.	1-24
Y	TAKAHASHI et al. Induction of CD8+ cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells. International Immunology. 1993, Vol. 5, No. 8, pages 849-857; especially pages 850-851 and 856.	1-24
Y	AUSTYN. Lymphoid dendritic cells. Immunology. 1987, Vol. 62, pages 161-170, see entire document, especially pages 162-164.	1-24
Y	KAYE et al. Nonphagocytic dendritic cells are effective accessory cells for anti-mycobacterial responses in vitro. Journal of Immunology. March 1985, Vol. 134, No. 3, pages 1930-1934, see entire document.	1-24
A	KNIGHT et al. Stimulatory and suppressive effects of infection of dendritic cells with HIV-1. Immunology Letters. 1991, Vol. 30, No. 2, pages 213-218, see entire document.	1-24

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER: \_\_\_\_\_**

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**